© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Twist Bioscience Corporation (TWST) stock declined over -1.81%, trading at $89.38 on NASDAQ, down from the previous close of $91.03. The stock opened at $89.71, fluctuating between $87.57 and $91.98 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Jul 08, 2026 | 90.08 | 91.98 | 87.57 | 89.38 | 1.72M |
| Jul 07, 2026 | 99.78 | 101.31 | 89.10 | 91.03 | 2.6M |
| Jul 06, 2026 | 96.80 | 104.40 | 95.00 | 99.93 | 1.45M |
| Jul 02, 2026 | 103.85 | 105.47 | 97.52 | 99.24 | 1.52M |
| Jul 01, 2026 | 101.16 | 104.65 | 99.91 | 102.25 | 1.5M |
| Jun 30, 2026 | 98.03 | 103.22 | 97.12 | 102.88 | 1.99M |
| Jun 29, 2026 | 100.00 | 101.08 | 96.32 | 98.36 | 1.66M |
| Jun 26, 2026 | 95.40 | 104.23 | 94.79 | 99.84 | 4.27M |
| Jun 25, 2026 | 93.14 | 98.40 | 91.88 | 96.65 | 2.78M |
| Jun 24, 2026 | 86.16 | 93.80 | 85.50 | 91.35 | 2.44M |
| Jun 23, 2026 | 82.29 | 87.54 | 81.55 | 85.00 | 1.77M |
| Jun 22, 2026 | 88.30 | 89.71 | 84.05 | 85.17 | 2.35M |
| Jun 18, 2026 | 85.67 | 87.77 | 84.13 | 87.56 | 3.94M |
| Jun 17, 2026 | 84.95 | 88.46 | 81.62 | 82.87 | 1.82M |
| Jun 16, 2026 | 81.02 | 86.94 | 80.63 | 84.95 | 2.48M |
| Jun 15, 2026 | 79.35 | 82.99 | 77.29 | 80.79 | 2.64M |
| Jun 12, 2026 | 75.02 | 78.28 | 75.01 | 76.17 | 2.61M |
| Jun 11, 2026 | 69.20 | 74.28 | 68.45 | 74.05 | 2.74M |
| Jun 10, 2026 | 69.40 | 71.77 | 67.24 | 67.77 | 1.15M |
| Jun 09, 2026 | 71.46 | 73.44 | 66.43 | 70.06 | 1.79M |
Twist Bioscience Corporation operates as a leading synthetic biology firm, specializing in the production and sale of products developed from synthesized DNA. The company utilizes a unique DNA synthesis platform that facilitates the creation of artificial DNA by "writing" it directly onto silicon chips. Its extensive product catalog encompasses custom synthetic genes, specialized tools designed for sample preparation, comprehensive antibody libraries essential for pharmaceutical research and development, and advanced applications leveraging DNA for digital data storage. Twist Bioscience has established strategic collaborations with several organizations, including Victorian Clinical Genetic Services, Vivlion GmbH, Kyowa Kirin Pharmaceutical Research, Inc., deepCDR Biologics AG, and Centogene N.V., with the shared goal of innovating advanced sequencing technologies. Furthermore, the company engages in a research alliance with Boehringer Ingelheim International GmbH, where it applies its exclusive antibody libraries to identify and develop therapeutic antibodies against a multitude of targets. The corporation was founded in 2013 and is headquartered in South San Francisco, California.
| Employees | 923 |
| Beta | 2.12 |
| Sales or Revenue | $376.57M |
| 5Y Sales Change% | 1.739% |
| Fiscal Year Ends | September |
| Sector | Healthcare |
| Industry | Medical - Diagnostics & Research |